Updated May 2024
| Trial Short Name | Molecular Target(s) | Patient Population | Lead Investigator(s) in Cambridge |
| ASCERTAIN | PARP | Newly diagnosed prostate cancer patients scheduled for curative radical prostatectomy. Randomised PARP, Darolutamide,PARP+Darolutamide. | S Pacey |
| ASTEROID | cIAP1/2 and XIAP | Advanced solid tumours refractory to immune checkpoint inhibitors. In combination with Pembrolizumab. | B Basu |
| ATRiUM | ATR | Solid tumours- ATR with gemcitabine. Particular interest in ARID1A mut, ATM loss | D Jodrell |
| AZD1390 | ATM with RT | Glioblastoma | R Jena |
|
AZD5305 (PETRA) |
PARP |
Advanced breast, prostate, ovarian, gatric cancers. With mutations in: BRCA1 / BRCA2 / PALB2 / RAD51. AZD5305 A PARP1-isoform selective 2nd-gen PARP inhibitor |
R Baird |
| AZD6738 | ATR | Ovarian cancer expansion (Post PARPi, BRCAm, platinum sensitive) | D Jodrell, B Basu |
| Basket of Baskets |
Multiple:
|
Advanced solid tumours- tumour DNA sequencing then therapy matched to molecular profile for subsets of patients:
|
R Baird |
| BEGONIA | TROP-2 targeted ADC | Metastatic TNBC. AKT inhibitor +/- Durvalumab/Paclitaxel | R Baird |
| BioNTech BNT142 | Claudine 16+ | NSCLC, ovary, endometrial, testicular | S.Pacey |
| Bluestar (AZD8205) | TOP1i | B7-H4 expressing tumours: breast, ovarian, endometrial | R Baird |
| BT5528 | EphA2 | Urothelial | B Basu |
| CONCORDE-B (NCT04550104): | ATM with RT | A study of a DNA damage response inhibitor (ATMi; AZD1390) in combination with conventional, radical radiotherapy in non-small cell lung cancer (stage IIb/III). | H Yang/D Jodrell |
| CCS1477 | P300/CBP | mCRPC or solid tumours with actionable target related to p300/CBP inhibition e.g. ARID1A/p300/CBP mt; / c-MYC amplification or tumour with high likelihood e.g. small cell cancer | S Pacey |
| CYCAD | Cyclin-E1 | CDK2 inhibitor. All comers escalation, ER+ HER2- breast and ovarian expansion | R.Baird |
| Determine | Rare genomic alterations/rare cancers | Umbrella trial. Adult/TYA/Paeds. Genotype-matched treatments outside of licensed indication. | B Basu |
| Heptares | EP4 | Solid tumours. | B Basu |
| INCA33890-101 | PD1 TGF-ß1 | All comers, expansions in PDAC and CRC | B Basu |
| NeoRay | GRPR | Neuroendocrine, prostate. Radiation dosimetry targeting gastrin releasing peptide receptor. Radiolabelling and therapeutic agent | L Aloj/S Pacey |
| Nurix 1607 (NCT05107674) | Immunomodulator | Advanced solid tumours without treatment options, CBL-B inhibitor | S Pacey |
| Petranha | PARPi | Prostate, AZD5305 in combination with new hormonal agents | S Pacey |
| TARGET | Genomic profiling on ctDNA | Matched to experimental medicine therapies based on molecular and clinical characteristics | B Basu |
